SMFM statement on NIH treatment guidelines
SMFM supports the new NIH COVID-19 Treatment guidelines.
SMFM supports the new NIH COVID-19 Treatment guidelines.
The following pertains to treatment for pregnant patients:
- Paxlovid (nirmatrelvir [PF-07321332] tablets and ritonavir tablets): no pregnancy data on nirmetrelvir, limited supply, consider drug-drug interactions
- Sotrovimab: limited supply that is mostly reserved for highest risk immunocompromised and elderly
- Remdesivir (3 day outpatient regimen): extensive pregnancy experience but requires multiple infusions
All of the above have similar efficacy at preventing hospitalization and death; despite no pregnancy-specific data
- Molnupiravir: 30% efficacy; EUA recommends against use in pregnancy but may reasonably consider use in pregnancy if no other therapies available and with documented counseling
Contemporary OB/GYN Senior Editor Angie DeRosa gets insight on the current state of COVID-19 from Christina Han, MD, division director of maternal-fetal medicine at the University of California, Los Angeles, and member of its COVID-19 task force. Han is an active member of the Society for Maternal-Fetal Medicine and discusses the issues on behalf of SMFM.
Listen
This Consult has been endorsed by the American College of Obstetricians and Gynecologists (ACOG) and replaces the Society for Maternal-Fetal Medicine's (SMFM) Statement #4, Implementation of the use of antenatal corticosteroids in the late preterm birth period in women at risk for preterm delivery, August 2016.
Read More
